[Federal Register: April 23, 2004 (Volume 69, Number 79)]
[Notices]
[Page 22055]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr23ap04-87]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Program Announcement 04084]
Development and Testing of New Antimalarial Drugs; Notice of
Intent To Fund Single Eligibility Award
A. Purpose
The Centers for Disease Control and Prevention (CDC) announces the
intent to fund fiscal year (FY) 2004 funds for a cooperative agreement
program to support research projects to develop and test new
antimalarial drugs. The Catalog of Federal Domestic Assistance number
for this program is 93.283.
B. Eligible Applicant
Assistance will be provided only to the University of Mississippi.
The FY 2000 United States Senate Labor-Health and Human Services
Appropriations Report: Report 106-166 (S 1650), recognized the unique
qualifications of the consortium headed by the University of
Mississippi School of Pharmacy, that includes the Department of
Medicinal Chemistry the Laboratory for Applied Drug Design and
Synthesis, the Thad Cochran Center for Natural Products, the Tulane
University Center for Infectious Diseases and the Tulane National
Primate Research Center for carrying out the activities specified in
this cooperative agreement and directed CDC to provide research funding
to the consortium. These organizations in the past three years have
worked in a unique partnership through a CDC cooperative agreement to
analyze and use natural products as antimalarial agents, set-up state
of the art chemical synthesis and organic product laboratories, refine
lead drug candidates and target molecules, conduct and organize phase I
and II clinical trials, and conduct in-vitro and in-vivo therapeutic
evaluations of drug activities and efficacies. No other consortia of
this type or identity as headed by the University of Mississippi School
of Pharmacy exists at this time in the public/academic realm that has
all these elements working together as a unit, which is necessary to
conduct rationale drug development. House Report 108-401 directed the
continuation of this work in FY 2004. The project supports the ongoing
activities of CDC in the global control and prevention of malaria and
the goals to protect Americans from infectious diseases and reduce the
spread of anti-microbial resistance.
C. Funding
Approximately $5,000,000 is available in FY 2004 to fund this
award. It is expected that the award will begin on or before August 1,
2004, and will be made for a 12-month budget period within a project
period of up to five years. Funding estimates may change.
D. Where To Obtain Additional Information
For general comments or questions about this announcement, contact:
Technical Information Management, CDC Procurement and Grants Office,
2920 Brandywine Road, Atlanta, GA 30341-4146, telephone: 770-488-2700.
For technical questions about this program, contact: John W.
Barnwell, Ph.D., MPH, Project Officer, 4770 Buford Highway, Atlanta, GA
30341, telephone: 770-488-4528, e-mail: wzb3@cdc.gov.
Dated: April 19, 2004.
William P. Nichols,
Acting Director, Procurement and Grants Office, Centers for Disease
Control and Prevention.
[FR Doc. 04-9239 Filed 4-22-04; 8:45 am]
BILLING CODE 4163-18-P